KR19990044460A - 아포리포단백질 에이-아이의 양을 증대시키는 티에노트리아졸로디아제핀의 용도 - Google Patents

아포리포단백질 에이-아이의 양을 증대시키는 티에노트리아졸로디아제핀의 용도 Download PDF

Info

Publication number
KR19990044460A
KR19990044460A KR1019980701708A KR19980701708A KR19990044460A KR 19990044460 A KR19990044460 A KR 19990044460A KR 1019980701708 A KR1019980701708 A KR 1019980701708A KR 19980701708 A KR19980701708 A KR 19980701708A KR 19990044460 A KR19990044460 A KR 19990044460A
Authority
KR
South Korea
Prior art keywords
compound
amount
apo
apolipoprotein
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019980701708A
Other languages
English (en)
Korean (ko)
Inventor
헤르만 켐펜
Original Assignee
프리돌린 클라우스너, 롤란드 비. 보레르
에프. 호프만-라 로슈 에이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프리돌린 클라우스너, 롤란드 비. 보레르, 에프. 호프만-라 로슈 에이지 filed Critical 프리돌린 클라우스너, 롤란드 비. 보레르
Publication of KR19990044460A publication Critical patent/KR19990044460A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1019980701708A 1995-09-09 1996-08-30 아포리포단백질 에이-아이의 양을 증대시키는 티에노트리아졸로디아제핀의 용도 Ceased KR19990044460A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95114163 1995-09-09
EP95114163.9 1995-09-09

Publications (1)

Publication Number Publication Date
KR19990044460A true KR19990044460A (ko) 1999-06-25

Family

ID=8219597

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019980701708A Ceased KR19990044460A (ko) 1995-09-09 1996-08-30 아포리포단백질 에이-아이의 양을 증대시키는 티에노트리아졸로디아제핀의 용도

Country Status (14)

Country Link
US (1) US5854238A (cg-RX-API-DMAC7.html)
EP (1) EP0853480B1 (cg-RX-API-DMAC7.html)
JP (1) JPH11512107A (cg-RX-API-DMAC7.html)
KR (1) KR19990044460A (cg-RX-API-DMAC7.html)
CN (1) CN1101680C (cg-RX-API-DMAC7.html)
AT (1) ATE230600T1 (cg-RX-API-DMAC7.html)
AU (1) AU725249B2 (cg-RX-API-DMAC7.html)
BR (1) BR9610390A (cg-RX-API-DMAC7.html)
CA (1) CA2230477A1 (cg-RX-API-DMAC7.html)
DE (1) DE69625696T2 (cg-RX-API-DMAC7.html)
DK (1) DK0853480T3 (cg-RX-API-DMAC7.html)
ES (1) ES2188783T3 (cg-RX-API-DMAC7.html)
TR (1) TR199800406T1 (cg-RX-API-DMAC7.html)
WO (1) WO1997009048A1 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6253569B1 (en) * 1999-05-07 2001-07-03 James J. Hall Portable storage unit for game animals
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US20040235877A1 (en) 2001-09-14 2004-11-25 Natsuki Ishizuka Novel use of tricyclic compound
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
KR20070089996A (ko) 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법
JP2010538005A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質e模倣ポリペプチドおよび使用方法
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
CN102292341B (zh) * 2008-10-30 2014-09-10 环行医学有限责任公司 对apo a有活性的噻吩并三唑并二氮杂*衍生物
CN103154246B (zh) 2010-05-14 2015-11-25 达那-法伯癌症研究所 用于治疗白血病的组合物和方法
ES2606958T3 (es) 2010-05-14 2017-03-28 Dana-Farber Cancer Institute, Inc. Compuestos de tienotriazolodiazepina para tratar una neoplasia
WO2011143651A1 (en) * 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
CN103180318B (zh) 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
US11446309B2 (en) 2013-11-08 2022-09-20 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
EP3099693A4 (en) 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
WO2015131113A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
JP7081923B2 (ja) 2014-07-31 2022-06-07 ユーエイビー リサーチ ファンデーション アポe模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果
WO2016022970A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
RU2017104897A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
UA122130C2 (uk) 2014-10-27 2020-09-25 Тенша Терапеутікс, Інк. Інгібітори бромодомену
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
EA202092635A1 (ru) 2018-06-13 2021-03-23 Дибли Аг Получение конденсированных производных триазепина и их применение в качестве ингибиторов bet

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12303A (en) * 1973-02-08 1979-01-16 Hoffmann La Roche Thienotriazolodiazepine derivatives
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
JPS50100096A (cg-RX-API-DMAC7.html) * 1974-01-08 1975-08-08

Also Published As

Publication number Publication date
AU725249B2 (en) 2000-10-12
BR9610390A (pt) 1999-07-06
DE69625696D1 (de) 2003-02-13
CN1101680C (zh) 2003-02-19
EP0853480A1 (en) 1998-07-22
US5854238A (en) 1998-12-29
EP0853480B1 (en) 2003-01-08
ES2188783T3 (es) 2003-07-01
WO1997009048A1 (en) 1997-03-13
DK0853480T3 (da) 2003-05-05
CN1195989A (zh) 1998-10-14
MX9801753A (es) 1998-08-30
ATE230600T1 (de) 2003-01-15
CA2230477A1 (en) 1997-03-13
AU6930396A (en) 1997-03-27
TR199800406T1 (en) 1998-05-21
JPH11512107A (ja) 1999-10-19
DE69625696T2 (de) 2003-10-16

Similar Documents

Publication Publication Date Title
EP0853480B1 (en) Use of a thienotriazolodiazepine to increase apolipoprotein a-i levels
US6136859A (en) Pharmaceutical formulation for treating liver disorders
EP1216024B1 (en) Formulation for menopausal women
US6852870B2 (en) Omega-3 fatty acids in the treatment of depression
WO1997039759A2 (en) Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
EP1269860B1 (en) Pharmaceutical composition
US6358937B1 (en) Method for the treatment of cancer using phosphatidic acid-comprising compositions
US7354906B2 (en) Composition of anti-HIV drugs and anti-cortisol compounds and method for decreasing the side effects of anti-HIV drugs in a human
EP0629400A1 (en) Idebenone compositions for treating Alzheimer's disease
US6447818B1 (en) Compositions containing compounds with adrenergic activity and vegetable extracts of Crataegus and gingko biloba for the treatment of overweight and obesity
US6344482B1 (en) Omega-3 fatty acids in the treatment of bipolar disorder
KR20010030928A (ko) 알콜중독자에게는 알콜 금단(禁斷) 증상과 음주욕구를억제하고, 그리고 건강한 사람에게는 과음을 예방하는조성물
JPS6299323A (ja) 高脂血症剤
JPH07330593A (ja) 疲労改善剤
EP1267892B1 (en) Use of cdp-choline for the treatment of alcohol withdrawal syndrome
DE60020833T2 (de) Melatonin zur behandlung von paralysen ausgelöst durch hirnschlag
US5627152A (en) Method for increasing bodyweight
MXPA98001753A (en) Use of a thenotriazolodiazepine to increase apolipoprotein levels
WO2003009840A1 (en) Composition comprising at least one lipase inhibitor and carnitine
US20040225010A1 (en) Method for decreasing cholesterol level in blood
KR20250088578A (ko) 베타-아드레날린 작용제 및 무스카린 길항제 조성물 및 사용 방법
JPH0436136B2 (cg-RX-API-DMAC7.html)
HK40036800A (en) Methods for increasing brain functionality using 2-fucosyl-lactose
HK1051784A1 (en) Pharmaceutical composition
HK1051784B (en) Pharmaceutical composition

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19980306

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20010829

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20030929

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20031230

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20030929

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I